In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: Different contribution of CYP2J2 in the small intestine and liver

Xenobiotica

Volumn 33, Issue 6, 2003, Pages 615-623

  Matsumoto, S ^a   Hirama, T ^a   Kim, H J ^a   Nagata, K ^a   Yamazoe, Y ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(4 FLUOROPHENYL)METHYL] 2 [[1 [2 (4 METHOXYPHENYL)ETHYL] 4 PIPERIDINYL]METHYL] 1H BENZIMIDAZOLE; 6 HYDROXYASTEMIZOLE; ALPHA NAPHTHOFLAVONE; ARACHIDONIC ACID; ASTEMIZOLE; COUMARIN; CYTOCHROME P450 2J2; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; INTESTINE ENZYME; KETOCONAZOLE; LIVER ENZYME; NORASTEMIZOLE; QUINIDINE; R 55248; SULFAPHENAZOLE; TERFENADINE; TRANYLCYPROMINE; TROGLITAZONE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; ENZYME INHIBITION; FIRST PASS EFFECT; HUMAN; INHIBITION KINETICS; LIVER MICROSOME; MALE; NONHUMAN; RABBIT; SMALL INTESTINE;

ANIMALS; ASTEMIZOLE; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HISTAMINE H1 ANTAGONISTS; HUMANS; INTESTINE, SMALL; LIVER; MASS SPECTROMETRY; MICROSOMES, LIVER; OXIDATION-REDUCTION; OXYGENASES; RECOMBINANT PROTEINS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0038095655     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000105778     Document Type: Article

References (22)

1. HASHIZUME, T., IMAOKA, S., MISE, M., TERAUCHI, Y., FUJII, T., MIYAZAKI, H., KAMATAKI, T. and FUNAE, Y., 2002, Involvement of CYP2J2 and CYP4F12 in the Metabolism of ebastine in human intestinal microsomes. Journal of Pharmacological and Experimental Therapeutics, 300, 298-304.
2. HASHIZUME, T., MISE, M., TERAUCHI, Y., LUAN, O., FUJII, T., MIYAZAKI, H. and INABA, T., 1998, N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metabolism and Disposition, 26, 566-571.
3. HEYKANTS, J., VAN PEER, A., WOESTENBORGHS, R., JAGENEAU, A. and VANDEN, B., 1986, Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. Drug Development Research, 8, 71-78.
4. JONES, B. C., HYLAND, R., ACKLAND, M., TYMAN, C. A. and SMITH, D. A., 1998, Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metabolism and Disposition, 26, 875-882.
5. LIN, J. H., CHIBA, M. and BAILLIE, T. A., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacological Review, 51, 135-158.
6. MATSUMOTO, S., HIRAMA, T., MATSUBARA, T., NAGATA, K. and YAMAZOE, Y., 2002, Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metabolism and Disposition, 30, 1240-1245.
7. MATSUMOTO, S. and YAMAZOE, Y., 2001, Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. British Journal of Clinical Pharmacology, 50, 1-11.
8. MEULDERMANS, W., HENDRICKX, J., LAUWERS, W., HURKMANS, R., SWYSEN, E. and HEYKANTS, J., 1986, Excretion and biotransformation of astemizole in rats, guinea-pigs, dogs, and man. Drug Development Research, 8, 37-51.
9. NAKAMURA, T., OKADA, K., NAGATA, K. and YAMAZOE, Y., 2000, Intestinal cytochrome P450 and response to rifampicin in rabbits. Japanese Journal of Pharmacology, 82, 232-239.
10. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
11. ONO, S., HATANAKA, T., HOTTA, H., SATOU, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using eDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
12. RICHARDS, D. M., BROGDEN, R. N., HEEL, R. C., SPEIGHT, T. M. and AVERY, G. S., 1984, Astemizole, a review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 28, 38-61.
13. SCARBOROUGH, P. E., MA, J., QU, W. and ZELDIN, D. C., 1999, P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metabolism Review, 31, 205-234.
14. TAAVITSAINEN, P., JUVONEN, R. and PELKONEN, O., 2001, In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition 29, 217-222.
15. THUMMEL, E. K., KUNZE, L. K. and SHEN, D. D., 1997, Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Review, 27, 99-127.
16. TORCHIN, C. D., MCNEILLY, P. J., KAPETANOVIC, I. M., STRONG, J. M. and KUPFERBERG, H. J., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metabolism and Disposition, 24, 1002-1008.
17. WU, S., MOOMAW, C. R., TOMER, K. B., FALCK, J. R. and ZELDIN, D. C., 1996, Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. Journal of Biological Chemistry, 271, 3460-3468.
18. YAMAGUCHI, T., HASHIZUME, T., MATSUDA, M., SAKASHITA, M., FUJII, T., SEKINE, Y., NAKASHIMA, M. and UEMATSU, T., 1994, Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung, 44, 59-64.
19. YAMAZAKI, H., SUZUKI, M., TANE, K., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2000, In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica, 1, 61-70.
20. ZELDIN, D. C., FOLEY, J., GOLDSWORTHY, S. M., COOK, M. E., BOYLE, J. E., MA, J., MOOMAW, C. R., TOMER, K. B., STEENBERGEN, C. and WU, S., 1997, CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Molecular Pharmacology, 51, 931-943.
21. ZELDIN, D. C., FOLEY, J., MA, J., BOYLE, J. E., PASCUAL, J. M., MOOMAW, C. R., TOMER, K. B., STEENBERGEN, C. and WU, S., 1996, CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Molecular Pharmacology, 50, 1111-1117.
22. ZHANG, W., KILICARSLAN, T., TYNDALE, R. F. and SELLERS, E. M., 2001, Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition, 29, 897-902.